TY - JOUR
T1 - Comparative Studies of Pharmacotherapy for School Refusal
AU - Bernstein, Gail A
AU - GARFINKEL, BARRY D.
AU - BORCHARDT, CARRIE M.
PY - 1990
Y1 - 1990
N2 - Two studies compared alprazolam and imipramine in the treatment of school refusal. In an open label study (N = 17), two-thirds of the subjects completing a trial in both the alprazolam and imipramine groups showed moderate to marked global improvement in symptoms of anxiety and depression. In the double-blind, placebo-controlled study (N = 24), posttreatment scores calculated as change from baseline on the Anxiety Rating for Children were significantly different (p = .03) among the three treatment groups, with the active medication groups showing the most improvement. Additionally, on all depression rating scales, similar trends were evident with the alprazolam and imipramine groups demonstrating greater improvement than the placebo group. However, analyses of covariance (with pretreatment scores as the covariates) showed no significant differences among the three treatment groups on change in anxiety and depression scales. Thus, additional research is needed to determine whether trends in this study are explained by drug effect or baseline differences on rating scales. J. Am. Acad. Child Adolesc. Psychiatry, 1990, 29, 5:773–781.
AB - Two studies compared alprazolam and imipramine in the treatment of school refusal. In an open label study (N = 17), two-thirds of the subjects completing a trial in both the alprazolam and imipramine groups showed moderate to marked global improvement in symptoms of anxiety and depression. In the double-blind, placebo-controlled study (N = 24), posttreatment scores calculated as change from baseline on the Anxiety Rating for Children were significantly different (p = .03) among the three treatment groups, with the active medication groups showing the most improvement. Additionally, on all depression rating scales, similar trends were evident with the alprazolam and imipramine groups demonstrating greater improvement than the placebo group. However, analyses of covariance (with pretreatment scores as the covariates) showed no significant differences among the three treatment groups on change in anxiety and depression scales. Thus, additional research is needed to determine whether trends in this study are explained by drug effect or baseline differences on rating scales. J. Am. Acad. Child Adolesc. Psychiatry, 1990, 29, 5:773–781.
KW - alprazolam
KW - imipramine
KW - school refusal
UR - http://www.scopus.com/inward/record.url?scp=0025102607&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025102607&partnerID=8YFLogxK
U2 - 10.1097/00004583-199009000-00016
DO - 10.1097/00004583-199009000-00016
M3 - Article
C2 - 2228932
AN - SCOPUS:0025102607
SN - 0890-8567
VL - 29
SP - 773
EP - 781
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
IS - 5
ER -